Advertisement
Advertisement
U.S. markets open in 2 hours 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4200-0.0400 (-1.63%)
At close: 04:00PM EDT
2.4300 +0.01 (+0.41%)
Pre-Market: 06:47AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close2.4600
Open2.3750
Bid2.4000 x 4000
Ask2.3900 x 900
Day's Range2.3100 - 2.5100
52 Week Range0.9900 - 2.6700
Volume6,147,186
Avg. Volume2,900,517
Market Cap913.422M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.3590
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GERN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Geron Corporation
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement